Focused antibody response to influenza linked to antigenic drift

Journal of Clinical Investigation

Volumn 125, Issue 7, 2015, Pages 2631-2645

  Huang, Kuan Ying A ^a   Rijal, Pramila ^b   Schimanski, Lisa ^b   Powell, Timothy J ^b   Lin, Tzou Yien ^a,c   McCauley, John W ^d   Daniels, Rodney S ^d   Townsend, Alain R ^b  

^a CHANG GUNG CHILDREN S HOSPITAL   (Taiwan)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^d THE FRANCIS CRICK INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN MONOCLONAL ANTIBODY; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; MONOCLONAL ANTIBODY; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS ANTIGEN;

AMINO ACID SUBSTITUTION; ANTIBODY RESPONSE; ANTIGENIC MODULATION; ARTICLE; CELL SURFACE; CODON; CONTROLLED STUDY; FLOW CYTOMETRY; HEMAGGLUTINATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO SELECTION; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; NONHUMAN; PLASMABLAST; PRIORITY JOURNAL; PROTEIN PURIFICATION; SEASONAL INFLUENZA; VIRUS TITRATION; ANIMAL; ANTIBODY SPECIFICITY; ANTIGENIC VARIATION; B LYMPHOCYTE; BIOSYNTHESIS; CHEMICAL STRUCTURE; CHEMISTRY; CROSS REACTION; FERRET; GENETIC DRIFT; GENETICS; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); METABOLISM; PROTEIN CONFORMATION;

AMINO ACID SUBSTITUTION; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; ANTIGENIC VARIATION; ANTIGENS, VIRAL; B-LYMPHOCYTES; CROSS REACTIONS; FERRETS; GENETIC DRIFT; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; MODELS, MOLECULAR; PROTEIN CONFORMATION;

EID: 84936797201     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI81104     Document Type: Article

References (68)

1. Barr IG, et al. WHO recommendations for the viruses used in the 2013-2014 Northern Hemisphere influenza vaccine: epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from October 2012 to January 2013. Vaccine. 2014;32(37):4713-4725.
2. Das SR, et al. Defining influenza A virus hemagglutinin antigenic drift by sequential monoclonal antibody selection. Cell Host Microbe. 2013;13(3):314-323.
3. Yewdell JW, Caton AJ, Gerhard W. Selection of influenza A virus adsorptive mutants by growth in the presence of a mixture of monoclonal antihemagglutinin antibodies. J Virol. 1986;57(2):623-628.
4. Hensley SE, et al. Hemagglutinin receptor binding avidity drives influenza A virus antigenic drift. Science. 2009;326(5953):734-736.
5. Gerber P, Loosli CG, Hambre D. Antigenic variants of influenza A virus, PR8 strain. I. Their development during serial passage in the lungs of partially immune mice. J Exp Med. 1955;101(6):627-638.
6. Daniels RS, et al. The receptor-binding and membrane-fusion properties of influenza virus variants selected using anti-haemagglutinin monoclonal antibodies. EMBO J. 1987;6(5):1459-1465.
7. Lin YP, et al. Evolution of the receptor binding properties of the influenza A(H3N2) hemagglutinin. Proc Natl Acad Sci U S A. 2012;109(52):21474-21479.
8. Haaheim LR. Haemagglutination-inhibition antibodies in human sera to an antigenic mutant of influenza A/Texas/1/77 (H3N2) virus obtained in vitro. Acta Pathol Microbiol Scand B. 1980;88(6):351-353.
9. Oxford JS, Haaheim LR, Slepushkin A, Werner J, Kuwert E, Schild GC. Strain specificity of serum antibody to the haemagglutinin of influenza A (H3N2) viruses in children following immunization or natural infection. J Hyg (Lond). 1981;86(1):17-26.
10. Natali A, Oxford JS, Schild GC. Frequency of naturally occurring antibody to influenza virus antigenic variants selected in vitro with monoclonal antibody. J Hyg (Lond). 1981;87(2):185-190.
11. Lambkin R, McLain L, Jones SE, Aldridge SL, Dimmock NJ. Neutralization escape mutants of type A influenza virus are readily selected by antisera from mice immunized with whole virus: A possible mechanism for antigenic drift. J Gen Virol. 1994;75(pt 12):3493-3502.
12. Popova L, et al. Immunodominance of antigenic site B over site A of hemagglutinin of recent H3N2 influenza viruses. PLoS One. 2012;7(7):e41895.
13. Wang ML, Skehel JJ, Wiley DC. Comparative analyses of the specificities of anti-influenza hemagglutinin antibodies in human sera. J Virol. 1986;57(1):124-128.
14. Linderman SL, et al. Potential antigenic explanation for atypical H1N1 infections among middle-aged adults during the 2013-2014 influenza season. Proc Natl Acad Sci U S A. 2014;111(44):15798-15803.
15. Xu R, Ekiert DC, Krause JC, Hai R, Crowe JE Jr, Wilson IA. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science. 2010;328(5976):357-360.
16. Wrammert J, et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature. 2008;453(7195):667-671.
17. Halliley JL, et al. Peak frequencies of circulating human influenza-specific antibody secreting cells correlate with serum antibody response after immunization. Vaccine. 2010;28(20):3582-3587.
18. Wu J, et al. Optimal vaccination strategies for 2009 pandemic H1N1 and seasonal influenza vaccines in humans. Vaccine. 2011;29(5):1009-1016.
19. Whittle JR, et al. Flow cytometry reveals that H5N1 vaccination elicits cross-reactive stemdirected antibodies from multiple Ig heavy-chain lineages. J Virol. 2014;88(8):4047-4057.
20. Smith K, et al. Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat Protoc. 2009;4(3):372-384.
21. International ImMunoGeneTics Information System. The global reference in immunogenetics and immunoinformatics. IMGT Web site. http://www.imgt.org. Updated March 05, 2015. Accessed April 17, 2015.
22. Li GM, et al. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc Natl Acad Sci U S A. 2012;109(23):9047-9052.
23. Thomson CA, et al. Pandemic H1N1 influenza infection and vaccination in humans induces cross-protective antibodies that target the hemagglutinin stem. Front Immunol. 2012;3:87.
24. Corti D, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science. 2011;333(6044):850-856.
25. Wrammert J, et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med. 2011;208(1):181-193.
26. Okuno Y, Isegawa Y, Sasao F, Ueda S. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J Virol. 1993;67(5):2552-2558.
27. Corti D, et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest. 2010;120(5):1663-1673.
28. Krause JC, et al. Epitope-specific human influenza antibody repertoires diversify by B cell intraclonal sequence divergence and interclonal convergence. J Immunol. 2011;187(7):3704-3711.
29. Jackson KJ, et al. Human responses to influenza vaccination show seroconversion signatures and convergent antibody rearrangements. Cell Host Microbe. 2014;16(1):105-114.
30. Worldwide Influenza Centre: Annual and interim reports. The Francis Crick Institute Web site. http:// crick.ac.uk/research/worldwide-influenza-centre/ annual-and-interim-reports. Updated February 25, 2015. Accessed April 17, 2015.
31. Barr IG, et al. A new pandemic influenza A(H1N1) genetic variant predominated in the winter 2010 influenza season in Australia, New Zealand and Singapore. Euro Surveill. 2010;15(42):19692.
32. Chen Z, et al. Generation of live attenuated novel influenza virus A/California/7/09 (H1N1) vaccines with high yield in embryonated chicken eggs. J Virol. 2010;84(1):44-51.
33. Gitlin AD, Shulman Z, Nussenzweig MC. Clonal selection in the germinal centre by regulated proliferation and hypermutation. Nature. 2014;509(7502):637-640.
34. Francis T. On The doctrine of original antigenic sin. P Am Philos Soc. 1960;104(6):572-578.
35. de St Groth F, Webster RG. Disquisitions of original antigenic sin. I. Evidence in man. J Exp Med. 1966;124(3):331-345.
36. Morens DM, Burke DS, Halstead SB. The wages of original antigenic sin. Emerg Infect Dis. 2010;16(6):1023-1024.
37. Li Y, et al. Immune history shapes specificity of pandemic H1N1 influenza antibody responses. J Exp Med. 2013;210(8):1493-1500.
38. Srivastava B, et al. Host genetic background strongly influences the response to influenza a virus infections. PLoS One. 2009;4(3):e4857.
39. Stevens J, Corper AL, Basler CF, Taubenberger JK, Palese P, Wilson IA. Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus. Science. 2004;303(5665):1866-1870.
40. Frolich D, et al. Secondary immunization generates clonally related antigen-specific plasma cells and memory B cells. J Immunol. 2010;185(5):3103-3110.
41. Moody MA, et al. H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination. PLoS One. 2011;6(10):e25797.
42. Okada J, et al. Monoclonal antibodies in man that neutralized H3N2 influenza viruses were classified into three groups with distinct strain specificity: 1968-1973, 1977-1993, and 1997-2003. Virology. 2010;397(2):322-330.
43. Okada J, et al. Localization of epitopes recognized by monoclonal antibodies that neutralized the H3N2 influenza viruses in man. J Gen Virol. 2011;92(pt 2):326-335.
44. Fonville JM, et al. Antibody landscapes after influenza virus infection or vaccination. Science. 2014;346(6212):996-1000.
45. Whittle JR, et al. Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc Natl Acad Sci U S A. 2011;108(34):14216-14221.
46. Hong M, et al. Antibody recognition of the pandemic H1N1 Influenza virus hemagglutinin receptor binding site. J Virol. 2013;87(22):12471-12480.
47. Lessler J, et al. Evidence for antigenic seniority in influenza A (H3N2) antibody responses in southern China. PLoS Pathog. 2012;8(7):e1002802.
48. Staudt LM, Gerhard W. Generation of antibody diversity in the immune response of BALB/c mice to influenza virus hemagglutinin. I. Significant variation in repertoire expression between individual mice. J Exp Med. 1983;157(2):687-704.
49. Clarke SH, Huppi K, Ruezinsky D, Staudt L, Gerhard W, Weigert M. Inter-and intraclonal diversity in the antibody response to influenza hemagglutinin. J Exp Med. 1985;161(4):687-704.
50. Radic M. Tracking and trapping somatic mutations in Ig genes. J Immunol. 2008;180(9):5763-5764.
51. Mozdzanowska K, Furchner M, Washko G, Mozdzanowski J, Gerhard W. A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro. J Virol. 1997;71(6):4347-4355.
52. Smith CA, Barnett BC, Thomas DB, Temoltzin-Palacios F. Structural assignment of novel and immunodominant antigenic sites in the neutralizing antibody response of CBA/Ca mice to influenza hemagglutinin. J Exp Med. 1991;173(4):953-959.
53. Nakajima S, Nobusawa E, Nakajima K. Variation in response among individuals to antigenic sites on the HA protein of human influenza virus may be responsible for the emergence of drift strains in the human population. Virology. 2000;274(1):220-231.
54. Skehel JJ, Wiley DC. Receptor binding and membrane fusion in virus entry: The influenza hemagglutinin. Annu Rev Biochem. 2000;69:531-569.
55. Haaheim LR, Tomasov CC, Barr IG, Hampson AW, Komadina N. Identification of genetic diversity by cultivating influenza A(H3N2) virus in vitro in the presence of post-infection sera from small children. Vaccine. 2006;24(44-46):6708-6711.
56. Yu X, et al. Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature. 2008;455(7212):532-536.
57. Miller MS, et al. antibodies against previously encountered influenza virus strains increase over time: A longitudinal analysis. Sci Transl Med. 2013;5(198):198ra107.
58. Manca F, Kunkl A, Fenoglio D, Fowler A, Sercarz E, Celada F. Constraints in T-B cooperation related to epitope topology on E. coli beta-galactosidase. I. The fine specificity of T cells dictates the fine specificity of antibodies directed to conformation-dependent determinants. Eur J Immunol. 1985;15(4):345-350.
59. Barnett BC, Graham CM, Burt DS, Skehel JJ, Thomas DB. The immune response of BALB/c mice to influenza hemagglutinin: commonality of the B cell and T cell repertoires and their relevance to antigenic drift. Eur J Immunol. 1989;19(3):515-521.
60. Watts C, et al. Modulation by epitope-specific antibodies of class II MHC-restricted presentation of the tetanus toxin antigen. Immunol Rev. 1998;164:11-16.
61. Shirai M, et al. T cell recognition of hypervariable region-1 from hepatitis C virus envelope protein with multiple class II MHC molecules in mice and humans: preferential help for induction of antibodies to the hypervariable region. J Immunol. 1999;162(1):568-576.
62. Moss CX, Tree TI, Watts C. Reconstruction of a pathway of antigen processing and class II MHC peptide capture. EMBO J. 2007;26(8):2137-2147.
63. Davila JG, Chowell G, Borja-Aburto VH, Viboud C, Grajales Muniz C, Miller M. Substantial morbidity and mortality associated with pandemic A/H1N1 influenza in Mexico, Winter 2013-2014: gradual age shift and severity. PLoS Curr. 2014;6:ecurrents.outbreaks.a855a92f19db1d-90ca955f5e908d6631.
64. Hai R, et al. Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility. Nat Commun. 2013;4:2854.
65. Powell TJ, Silk JD, Sharps J, Fodor E, Townsend AR. Pseudotyped influenza A virus as a vaccine for the induction of heterotypic immunity. J Virol. 2012;86(24):13397-13406.
66. Kinoshita K, Shimizu A, Honjo T. The membrane exons of the pseudo-γ-chain gene of the human immunoglobulin are apparently functional and highly homologous to those of the γ 1 gene. Immunol Lett. 1991;27(2):151-155.
67. Rowe T, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol. 1999;37(4):937-943.
68. Matrosovich M, Matrosovich T, Carr J, Roberts NA, Klenk HD. Overexpression of the α-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. J Virol. 2003;77(15):8418-8425.